A5087378414- Lymphoma Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Cardiac tumors and thrombi
- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Hematological disorders and diagnostics
- Acute Myeloid Leukemia Research
- Neutropenia and Cancer Infections
Wenzhou Medical University
2020-2025
First Affiliated Hospital of Wenzhou Medical University
2020-2025
Mantle cell lymphoma (MCL) exhibits significant biological and clinical heterogeneity, necessitating a refined prognostic model. According to the drawbacks of existing models which do not truly define complexity disease, we used molecular data from nine medical centers China validate predictive utility progression disease within 24 months (POD24), also established novel risk model predict survival outcome MCL patients. POD24 occurred in 37.7% evaluable patients, with median over being 21...
<title>Abstract</title> Mantle cell lymphoma (MCL) exhibits significant biological and clinical heterogeneity, necessitating a refined prognostic model. According to the drawback of models existed which are not truly define complexity disease, we used molecular data from nine medical centers China validate predictive utility in progression disease within 24 months (POD24), also establish novel risk model predict survival outcome MCL patients. POD24 occurred 37.7% evaluable patients, with...
Abstract Background : Acute myeloid leukemia(AML) is a highly heterogeneous hematological malignancy. Despite, increase in treatment options for AML over the past decade, prognosis remain dismal. Numerous prognostic models have been developed this disease, however nomograms predicting long-term survival patients after induction chemotherapy(IA regimen) not described. Method We constructed to predict disease-free survival(DFS) and overall survival(OS) by analyzing cohort of with de novo...